Gerald Spotts

2.9k citations

43 papers · 1.7k indexed · h-index 20

Hematology top 1%
- Hemophilia Treatment and Research 29
- Platelet Disorders and Treatments 12
- Blood Coagulation and Thrombosis Mechanisms 12
- Chronic Myeloid Leukemia Treatments 9
Virology top 2%
- HIV Research and Treatment 12
Genetics top 5%
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 4
Immunology top 10%
- T-cell and B-cell Immunology 7
- Immune Cell Function and Interaction 7
Infectious Diseases top 10%

Co-authors: Bruce M. Ewenstein Victor S. Blanchette Kathelijn Fischer Frederick Hecht P Schroth M. Oh S. Fritsch Douglas F. Nixon
Cited by: Hematology Virology Genetics
Journals: Blood (11 papers)Journal of Thrombosis and Haemostasis (6 papers)Haemophilia (6 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Gerald Spotts

42 papers receiving 1.6k citations

Peers

Countries citing papers authored by Gerald Spotts

Since Specialization

Citations

This map shows the geographic impact of Gerald Spotts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Spotts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Spotts more than expected).

Fields of papers citing papers by Gerald Spotts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Spotts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Spotts. The network helps show where Gerald Spotts may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gerald Spotts, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerald Spotts Line = papers co-authored together Gerald Spotts links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis Thrombosis and Haemostasis ·Pratima Chowdary,Kathelijn Fischer,Peter W. Collins,Bernd Nusser,Barbara A. Konkle,Victor S. Blanchette,Steven W. Pipe,Erik Berntorp,Martin J. Wolfsegger,Werner Engl,Gerald Spotts	2020	20
2	Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method Biologics ·Erik Berntorp,Gerald Spotts,Lisa Patrone,Bruce M. Ewenstein	2014	22
3	Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study Annals of Hematology ·Michelle Sharpe,Robert Klamroth,Natascha Vidovic,J Paineau,J. Epstein,F Di Gregorio,Gerald Spotts,Johannes Oldenburg	2013	9
4	Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection PLoS ONE ·Stéphane Champiat,Rui André Saraiva Raposo,Nicholas J. Maness,Maxwell Rapp,西松和彦,RANGASWAMI AYYANGAR G.N,Internationalization Task Force,Hansi Dean,Wayne C. Koff,Marisa Ailin Hong,Jeffrey N. Martin,Steven G. Deeks,Gerald Spotts,Christopher D. Pilcher,Frederick Hecht,Esper G. Kallás,Keith Garrison,Douglas F. Nixon	2012	17
5	Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients Haemophilia ·J. Epstein,Yan Xiong,P Woo,X. Wang,Gerald Spotts	2011	7
6	Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials Haemophilia ·Kathelijn Fischer,Peter W. Collins,Sven Björkman,Victor S. Blanchette,M. Oh,S. Fritsch,P Schroth,Gerald Spotts,Bruce M. Ewenstein	2011	36
7	Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring Journal of Thrombosis and Haemostasis ·Sven Björkman,Victor S. Blanchette,Kathelijn Fischer,M. Oh,Gerald Spotts,P Schroth,S. Fritsch,Lisa Patrone,Bruce M. Ewenstein,Peter W. Collins	2010	99
8	Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes PLoS ONE ·Christian B. Willberg,Keith Garrison,R. Brad Jones,R.M. Diamond,Gerald Spotts,Teri Liegler,Oluwatosin A. Adebayo,Annika C. Karlsson,Frederick Hecht,Douglas F. Nixon	2010	14
9	Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice Haemophilia ·Johannes Oldenburg,Jenny Goudemand,Leonard A. Valentino,Michael Richards,Hung S. Luu,J Paineau,Robert A. Verrey,Gerald Spotts,Bruce M. Ewenstein	2010	22
10	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens Journal of Thrombosis and Haemostasis ·Peter W. Collins,Sven Björkman,Kathelijn Fischer,Victor S. Blanchette,M. Oh,P Schroth,S. Fritsch,Kathleen Casey,Gerald Spotts,Bruce M. Ewenstein	2009	147
11	The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions Lund University Publications (Lund University) ·P. Collins,Jan Astermark,Rahmanpour Mohammad,Sven Björkman,K. Fischer,김성아,P Schroth,Mostafa yehia,Minseok Oh,Gerald Spotts,K. Nordling	2008	3
12	Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A Journal of Thrombosis and Haemostasis ·P. Collins,Victor S. Blanchette,Kathelijn Fischer,Masumeh Samari-Khalaj,M. Oh,S. Fritsch,P Schroth,Gerald Spotts,Jan Astermark,Bruce M. Ewenstein	2008	262
13	Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients Journal of Thrombosis and Haemostasis ·Victor S. Blanchette,Amy D. Shapiro,Ri Liesner,Felipe Navarro,Indira Warrier,P Schroth,Gerald Spotts,Bruce M. Ewenstein	2008	120
14	T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection PLoS Pathogens ·Keith Garrison,R. Brad Jones,Duncan A. Meiklejohn,Naveed Anwar,Lishomwa C. Ndhlovu,Joan M. Chapman,Ann L. Erickson,Ashish Agrawal,Gerald Spotts,Frederick Hecht,Seth Rakoff-Nahoum,Jack Lenz,Mario Ostrowski,Douglas F. Nixon	2007	105
15	Immune Reconstitution of CD56^dimNK Cells in Individuals with Primary HIV‐1 Infection Treated with Interleukin‐2 The Journal of Infectious Diseases ·Jakob Michaëlsson,Brian Long,Christopher P. Loo,Lewis L. Lanier,Gerald Spotts,Frederick Hecht,Douglas F. Nixon	2007	22
16	Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8⁺T_EMRACells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point Journal of Virology ·John Northfield,Christopher P. Loo,Jason D. Barbour,Gerald Spotts,Frederick Hecht,Paul Klenerman,Douglas F. Nixon,Jakob Michaëlsson	2007	64
17	Elevations in IL-10, TNF- α , and IFN- γ from the Earliest Point of HIV Type 1 Infection AIDS Research and Human Retroviruses ·Philip J. Norris,Brandee Pappalardo,Brian Custer,Gerald Spotts,Frederick Hecht,Michael P. Busch	2006	95
18	Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion Blood Coagulation & Fibrinolysis ·C. Fevola,Aaron G. McCullough,R.N. Harada,향가흔,Gerald Spotts	2006	12
19	Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance AIDS ·Grant Colfax,Eric Vittinghoff,Robert M. Grant,Paula J. Lum,Gerald Spotts,Frederick Hecht	2006	42
20	Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method1Proceedings of a special symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12–18, 2003, Birmingham, UK Seminars in Hematology* ·Bruce M. Ewenstein,Peter W. Collins,Michael D. Tarantino,Claude Négrier,Victor S. Blanchette,Merris D. Obie,Derek Baker,Gerald Spotts,Martha G. Sensel,Nichakan Inthitanon	2004	13

About Gerald Spotts

Gerald Spotts is a scholar working on Hematology, Virology, Genetics, Immunology and Infectious Diseases, having authored 43 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (29 papers), HIV Research and Treatment (12 papers), Platelet Disorders and Treatments (12 papers), Blood Coagulation and Thrombosis Mechanisms (12 papers), Chronic Myeloid Leukemia Treatments (9 papers), T-cell and B-cell Immunology (7 papers), Immune Cell Function and Interaction (7 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers). The work is most often cited by research in Hematology (1.0k citations), Virology (351 citations), Genetics (288 citations), Immunology (362 citations) and Infectious Diseases (129 citations). Gerald Spotts has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Bruce M. Ewenstein, Victor S. Blanchette, Kathelijn Fischer, Frederick Hecht, P Schroth, M. Oh, S. Fritsch, Douglas F. Nixon, Peter W. Collins and Sven Björkman. Their work appears in journals such as Blood, Journal of Thrombosis and Haemostasis, Haemophilia, PLoS ONE and Seminars in Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact